← Back to headlines
NervGen Stock Rises Following TD Cowen's New 'Buy' Rating
NervGen's stock experienced a rise after TD Cowen issued a new 'Buy' rating for the company's lead asset, signaling positive market sentiment.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Irish Health Agency Fined €645,000 for Storing Records in Derelict Sites
2h ago
New Urine Test Detects Over 90 Percent of Bladder Cancer Cases
3h ago
Swimmer Hospitalized Following Suspected Shark Attack in Massachusetts
6h ago
Wellington Clinics Suspends Kidney Transplants Amid Organ Harvesting Probe
12h ago